Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 150 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand		 Sheep,
Cattle		 Granted
New
Zealand		 Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle		 Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle		 Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig		 Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Press Release

New registration for Tri-Solfen® expands commercial reach in New Zealand

May 14, 2019

Label extension for the Group’s innovative pain mitigation product includes use on calves following disbudding procedure

Government legislation in New Zealand to prohibit the disbudding of calves without appropriate analgesics from October 1st 2019

Tri-Solfen® is currently the only approved topical pain and wound management product for use in livestock undergoing painful husbandry procedures globally

Melbourne, Australia – 13th May 2019 – Medical Ethics Pty Ltd (“Medical Ethics” or “the Group”), a commercial and product development company focused on pain mitigation in wounds for humans and animals, announces that with its New Zealand marketing and distribution partner Bayer Animal Health it has successfully registered Tri-Solfen® in New Zealand for hot iron cautery disbudding procedures in calves. This marks the fifth approval for the Group’s innovative pain mitigation product in animal husbandry procedures. Tri-Solfen® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improve wound healing.

The approval was granted by the Ministry for Primary Industries, New Zealand’s governing body for animal welfare, and precedes an upcoming change in legislation which will prohibit the disbudding of calves without appropriate analgesics. To remove potentially dangerous horns, over two million calves undergo painful hot iron disbudding procedures each year in New Zealand. Tri-Solfen® represents the only approved topical pain and wound management product for use in livestock undergoing such painful husbandry procedures globally.

In conjunction with the approval, Bayer Animal Health hosted over 400 veterinarians for a launch event which highlighted the new use for Tri-Solfen®. The new commercial opportunity expands on the products’ existing remit which includes pain relief for certain livestock after tail docking and castration.

Andrew Bosch, Brand Manager at Bayer Animal Health, commented:
“Broadening the approved use of Tri-Solfen®, which is proven to deliver a highly effective, practical and cost-efficient solution for pain mitigation in animals, is a positive development in helping to ease some of the animal welfare pressures that face modern day farming communities. At Bayer Animal Health, we are committed to improving animal wellbeing by bringing best-in-class products to farmers and veterinarians and we continue to work with Medical Ethics on approvals for further indications and claims for Tri-Solfen® in New Zealand.”

Allan Giffard, Managing Director of Medical Ethics, added:
“With new legislation prohibiting the disbudding of calves without appropriate analgesics coming into force on the 1st of October 2019, this is an important registration for Tri-Solfen® as the only approved topical pain and wound management product for use in livestock undergoing such painful husbandry procedures. It is also another endorsement of our technology and dedication to improving animal welfare across the globe. We look forward to expanding our current offering in New Zealand, building on the enormous success in Australia and expanding our global market approvals with our international marketing partner Dechra Pharmacuticals.”

Further information

Medical Ethics:

Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286

FTI Consulting:

Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000